


BioVendor

Research
and Diagnostic Products



HUMAN LIF ELISA

Product Data Sheet

Cat. No.: RBMS242R

For Research Use Only

CONTENTS

| | | |
|----|--|----|
| 1 | INTENDED USE | 3 |
| 2 | SUMMARY | 3 |
| 3 | PRINCIPLES OF THE TEST | 5 |
| 4 | REAGENTS PROVIDED | 6 |
| 5 | STORAGE INSTRUCTIONS – ELISA.KIT | 7 |
| 6 | SPECIMEN COLLECTION AND STORAGE INSTRUCTIONS | 7 |
| 7 | MATERIALS REQUIRED BUT NOT PROVIDED | 7 |
| 8 | PRECAUTIONS FOR USE | 8 |
| 9 | PREPARATION OF REAGENTS | 9 |
| 10 | TEST PROTOCOL | 12 |
| 11 | CALCULATION OF RESULTS | 14 |
| 12 | LIMITATIONS | 16 |
| 13 | PERFORMANCE CHARACTERISTICS | 17 |
| 14 | REFERENCES | 21 |
| 15 | REAGENT PREPARATION SUMMARY | 23 |
| 16 | TEST PROTOCOL SUMMARY | 24 |

**»» This kit is manufactured by:
BioVendor – Laboratorní medicína, a.s.**

»» Use only the current version of Product Data Sheet enclosed with the kit!

1 INTENDED USE

The human LIF ELISA is an enzyme-linked immunosorbent assay for the quantitative detection of human LIF. **The human LIF ELISA is for research use only. Not for diagnostic or therapeutic procedures.**

2 SUMMARY

Leukemia inhibitory factor (LIF) is a cytokine which was primarily described as a product of activated T lymphocytes (13) and macrophages (3). It is a variably glycosylated 180 amino acid protein of apparent molecular weight between 35 and 67 kDa depending on its source and glycosylation (7, 8). The human LIF-gene is located on chromosome 22, the gene product is highly conserved between species. The multivarious nature of LIF is illustrated by its multiple "discoveries" under a variety of synonyms:

| Abbreviation | Name |
|--------------|---|
| D-factor | Differentiation-inducing factor |
| LIF | Leukemia inhibitory factor |
| DIF | Differentiation-inducing factor |
| DIA | Differentiation-inducing activity |
| DRF | Differentiation-retarding factor |
| HSF III | Hepatocyte-stimulating factor |
| MLPLI | Melanoma-derived lipoprotein lipase inhibitor |
| HILDA | Human interleukin for DA-1 cells |
| CNDF | Cholinergic neuronal differentiation factor |
| OAL | Osteoclast-activating factor |

LIF is a member of a family of cytokines composed of Oncostatin-M, Interleukin 6, Interleukin 11, ciliary neurotrophic factor and granulocyte colony-stimulating factor.

These factors are related based on sequence homology, chromosome location, and the structure of their receptors (18). The receptors used by this family all share a common and obligatory component, namely the gp130 subunit, originally identified as a signal transducer for IL-6 (24).

LIF exerts its pleiotropic functions in a wide variety of systems. Examples for its important and diverse physiological functions are support of growth and inhibition of differentiation of normal embryonic stem cells (19, 24), stimulation of the production of acute-phase proteins by hepatocytes (4). LIF is able to potentiate interleukin 3 capacity to enhance megakaryocytic differentiation of myeloid progenitors (12) and to stimulate bone resorption and new bone formation (1, 17). In neural development, LIF induces an upregulation of neuropeptides and acetylcholine synthesis in sympathetic neurons (25) and is a neurotrophic survival factor (15, 10). There is furthermore emerging evidence to suggest that LIF overproduction during acute or chronic inflammatory conditions may be responsible for some of the deranged physiological manifestations of disease. A variety of human tumour lines have been shown to constitutively produce detectable levels of LIF (6) while generally LIF expression is induced by stimulatory factors.

A soluble form of LIF can be detected in human body fluids such as serum, whole blood, synovial fluid and urine, quantitative assessment of the cytokine in normal subjects and of patients suffering from a variety of diseases helps to get insight into various pathological situations.

It furthermore turned out to be of crucial significance to detect the glycosylated form of the LIF protein by usage of antibodies raised against this molecule and a glycosylated calibrator (20).

It has been shown that levels of LIF in blood, urine and other body fluids are increased in definite biological abnormalities such as hypercalcemia, polycythemia, erythropoietic crisis, hyperthrombocythemia (14); during acute rejection of allograft transplants, especially kidney; in osteoporosis.

Increased plasma levels of LIF in sepsis correlate with shock and poor prognosis (22).


It is also known to play a major role in human inflammatory lung diseases (21) and generally in acute and chronic inflammations including pneumonia, Rheumatoid arthritis (5) (serum and synovial levels elevated), carcinoma (adenocarcinoma, mesothelioma, melanoma (16), peritonitis. LIF concentration in the bone marrow-plasma of patients with hematologic malignancies are significantly elevated (11). Leukemia inhibitory factor concentrations were significantly elevated in amniotic fluid in association with intraamniotic infection (9).

3 PRINCIPLES OF THE TEST

An anti-human LIF coating antibody is adsorbed onto microwells.

Figure 1


Coated Microwell



Human LIF present in the sample or standard binds to antibodies adsorbed to the microwells.

Figure 2


First Incubation



Following incubation unbound biological components are removed during a wash step. A biotin-conjugated anti-human LIF antibody is added and binds to human LIF captured by the first antibody.

Figure 3


Second Incubation



Following incubation unbound biotin-conjugated anti-human LIF antibody is removed during a wash step. Streptavidin-HRP is added and binds to the biotin-conjugated anti-human LIF antibody.


Figure 4

Third Incubation




Following incubation unbound Streptavidin-HRP is removed during a wash step, and substrate solution reactive with HRP is added to the wells.

Figure 5



A coloured product is formed in proportion to the amount of human LIF present in the sample or standard. The reaction is terminated by addition of acid and absorbance is measured at 450 nm. A standard curve is prepared from 7 human LIF standard dilutions and human LIF sample concentration determined.

Figure 6



4 REAGENTS PROVIDED

- 1 aluminium pouch with a **Antibody Coated Microtiter Strips** with monoclonal antibody to human LIF
- 1 vial (200 µl) **Biotin-Conjugate** anti-human LIF monoclonal antibody
- 1 vial (150 µl) **Streptavidin-HRP**
- 2 vials (300 µl) human LIF **Standard**, 400 pg/ml
- 1 vial (12 ml) **Sample Diluent**
- 1 vial (12 ml) **Biotin Diluent**
- 1 vial (5 ml) **Assay Buffer Concentrate** 20x (PBS with 1% Tween 20 and 10% BSA)
- 1 bottle (50 ml) **Wash Buffer Concentrate** 20x (PBS with 1% Tween 20)
- 1 vial (15 ml) **Substrate Solution** (tetramethyl-benzidine)
- 1 vial (12 ml) **Stop Solution** (1M Phosphoric acid)
- 1 vial (0.4 ml) **Blue-Dye**
- 1 vial (0.4 ml) **Green-Dye**
- 1 vial (0.4 ml) **Red-Dye**
- 6 **Adhesive Films**

5 STORAGE INSTRUCTIONS – ELISA.KIT

Store kit reagents between 2° and 8°C. Immediately after use remaining reagents should be returned to cold storage (2° to 8°C). Expiry of the kit and reagents is stated on labels.

Expiry of the kit components can only be guaranteed if the components are stored properly, and if, in case of repeated use of one component, this reagent is not contaminated by the first handling.

6 SPECIMEN COLLECTION AND STORAGE INSTRUCTIONS

Cell culture supernatant, serum and plasma (EDTA, citrate, heparin) were tested with this assay. Other biological samples might be suitable for use in the assay.

Remove serum or plasma from the clot or cells as soon as possible after clotting and separation.

Samples containing a visible precipitate must be clarified prior to use in the assay. Do not use grossly hemolyzed or lipemic specimens.

Samples should be aliquoted and must be stored frozen at -20°C to avoid loss of bioactive human LIF. If samples are to be run within 24 hours, they may be stored at 2° to 8°C (for sample stability refer to 13.5).

Avoid repeated freeze-thaw cycles. Prior to assay, the frozen sample should be brought to room temperature slowly and mixed gently.

7 MATERIALS REQUIRED BUT NOT PROVIDED

- 5 ml and 10 ml graduated pipettes
- 5 µl to 1000 µl adjustable single channel micropipettes with disposable tips
- 50 µl to 300 µl adjustable multichannel micropipette with disposable tips
- Multichannel micropipette reservoir
- Beakers, flasks, cylinders necessary for preparation of reagents
- Device for delivery of wash solution (multichannel wash bottle or automatic wash system)
- Microwell strip reader capable of reading at 450 nm (620 nm as optional reference wave length)
- Glass-distilled or deionized water
- Statistical calculator with program to perform regression analysis

8 PRECAUTIONS FOR USE

- All chemicals should be considered as potentially hazardous. We therefore recommend that this product is handled only by those persons who have been trained in laboratory techniques and that it is used in accordance with the principles of good laboratory practice. Wear suitable protective clothing such as laboratory overalls, safety glasses and gloves. Care should be taken to avoid contact with skin or eyes. In the case of contact with skin or eyes wash immediately with water. See material safety data sheet(s) and/or safety statement(s) for specific advice.
- Reagents are intended for research use only and are not for use in diagnostic or therapeutic procedures.
- Do not mix or substitute reagents with those from other lots or other sources.
- Do not use kit reagents beyond expiration date on label.
- Do not expose kit reagents to strong light during storage or incubation.
- Do not pipette by mouth.
- Do not eat or smoke in areas where kit reagents or samples are handled.
- Avoid contact of skin or mucous membranes with kit reagents or specimens.
- Rubber or disposable latex gloves should be worn while handling kit reagents or specimens.
- Avoid contact of substrate solution with oxidizing agents and metal.
- Avoid splashing or generation of aerosols.
- In order to avoid microbial contamination or cross-contamination of reagents or specimens which may invalidate the test use disposable pipette tips and/or pipettes.
- Use clean, dedicated reagent trays for dispensing the conjugate and substrate reagent.
- Exposure to acid inactivates the conjugate.
- Glass-distilled water or deionized water must be used for reagent preparation.
- Substrate solution must be at room temperature prior to use.
- Decontaminate and dispose specimens and all potentially contaminated materials as they could contain infectious agents. The preferred method of decontamination is autoclaving for a minimum of 1 hour at 121.5°C.
- Liquid wastes not containing acid and neutralized waste may be mixed with sodium hypochlorite in volumes such that the final mixture contains 1.0% sodium hypochlorite. Allow 30 minutes for effective decontamination. Liquid waste containing acid must be neutralized prior to the addition of sodium hypochlorite.

9 PREPARATION OF REAGENTS

Buffer Concentrates should be brought to room temperature and should be diluted before starting the test procedure.

If crystals have formed in the **Buffer Concentrates**, warm them gently until they have completely dissolved.

9.1 Wash Buffer (1x)

Pour entire contents (50 ml) of the **Wash Buffer Concentrate** (20x) into a clean 1000 ml graduated cylinder. Bring to final volume of 1000 ml with glass-distilled or deionized water. Mix gently to avoid foaming. The pH of the final solution should adjust to 7.4.

Transfer to a clean wash bottle and store at 2° to 25°C. Please note that Wash Buffer (1x) is stable for 30 days.

Wash Buffer (1x) may also be prepared as needed according to the following table:

| Number of Strips | Wash Buffer Concentrate (20x) (ml) | Distilled Water (ml) |
|------------------|------------------------------------|----------------------|
| 1 - 6 | 25 | 475 |
| 1 - 12 | 50 | 950 |

9.2 Assay Buffer (1x)

Pour the entire contents (5 ml) of the **Assay Buffer Concentrate** (20x) into a clean 100 ml graduated cylinder. Bring to final volume of 100 ml with distilled water. Mix gently to avoid foaming.

Store at 2° to 8°C. Please note that the Assay Buffer (1x) is stable for 30 days.

Assay Buffer (1x) may also be prepared as needed according to the following table:

| Number of Strips | Assay Buffer Concentrate (20x) (ml) | Distilled Water (ml) |
|------------------|-------------------------------------|----------------------|
| 1 - 6 | 2.5 | 47.5 |
| 1 - 12 | 5.0 | 95.0 |

9.3 Biotin-Conjugate

Please note that the Biotin-Conjugate should be used within 30 minutes after dilution.

Make a 1:100 dilution of the concentrated **Biotin-Conjugate** solution with Biotin Diluent in a clean plastic tube as needed according to the following table:

| Number of Strips | Biotin-Conjugate (ml) | Biotin Diluent (ml) |
|------------------|-----------------------|---------------------|
| 1 - 6 | 0.06 | 5.94 |
| 1 - 12 | 0.12 | 11.88 |

9.4 Streptavidin-HRP

Please note that the Streptavidin-HRP should be used within 30 minutes after dilution.

Make a 1:160 dilution of the concentrated **Streptavidin-HRP** solution with Assay Buffer (1x) in a clean plastic tube as needed according to the following table:

| Number of Strips | Streptavidin-HRP (ml) | Assay Buffer (1x) (ml) |
|------------------|-----------------------|------------------------|
| 1 - 6 | 0.038 | 5.962 |
| 1 - 12 | 0.075 | 11.925 |

9.5 Human LIF Standard

Standard dilutions can be prepared directly on the microwell plate (see 10.c) or alternatively in tubes (see 9.5.1).

9.5.1 External Standard Dilution

Label 7 tubes, one for each standard point.

S1, S2, S3, S4, S5, S6, S7

Then prepare 1:2 serial dilutions for the standard curve as follows:


Pipette 225 μ l of Sample Diluent into each tube.

Pipette 225 μ l of undiluted standard (concentration = 400 pg/ml) into the first tube, labelled S1, and mix (concentration of standard 1 = 200 pg/ml). Pipette 225 μ l of this dilution into the second tube, labelled S2, and mix thoroughly before the next transfer.

Repeat serial dilutions 5 more times thus creating the points of the standard curve a (see Figure 7).

Sample Diluent serves as blank.

Figure 7



9.6 Addition of Colour-giving Reagents: Blue-Dye, Green-Dye, Red-Dye

This procedure is optional, does not in any way interfere with the test results, and is designed to help the customer with the performance of the test, but can also be omitted, just following the instruction booklet.

Alternatively, the dye solutions from the stocks provided (**Blue-Dye**, **Green-Dye**, **Red-Dye**) can be added to the reagents according to the following guidelines:

1. Diluent: Before standard and sample dilution add the **Blue-Dye** at a dilution of 1:250 (see table below) to the appropriate diluent (1x) according to the test protocol. After addition of **Blue-Dye**, proceed according to the instruction booklet.

| | |
|----------------------|------------------------|
| 5 ml Sample Diluent | 20 µl Blue-Dye |
| 12 ml Sample Diluent | 48 µl Blue-Dye |
| 50 ml Sample Diluent | 200 µl Blue-Dye |

2. Biotin-Conjugate: Before dilution of the concentrated Biotin-Conjugate, add the **Green-Dye** at a dilution of 1:100 (see table below) to the Biotin Diluent used for the final conjugate dilution. Proceed after addition of **Green-Dye** according to the instruction booklet: Preparation of Biotin-Conjugate.

| | |
|----------------------|-------------------------|
| 6 ml Biotin Diluent | 60 µl Green-Dye |
| 12 ml Biotin Diluent | 120 µl Green-Dye |


3. Streptavidin-HRP: Before dilution of the concentrated Streptavidin-HRP, add the **Red-Dye** at a dilution of 1:250 (see table below) to the Assay Buffer (1x) used for the final Streptavidin-HRP dilution. Proceed after addition of **Red-Dye** according to the instruction booklet: Preparation of Streptavidin-HRP.

| | |
|-------------------------|----------------------|
| 6 ml Assay Buffer (1x) | 24 µl Red-Dye |
| 12 ml Assay Buffer (1x) | 48 µl Red-Dye |

10 TEST PROTOCOL

- Determine the number of microwell strips required to test the desired number of samples plus appropriate number of wells needed for running blanks and standards. Each sample, standard, blank and optional control sample should be assayed in duplicate. Remove extra microwell strips from holder and store in foil bag with the desiccant provided at 2°-8°C sealed tightly.
- Wash the microwell strips twice with approximately 400 µl **Wash Buffer** per well with thorough aspiration of microwell contents between washes. Allow the Wash Buffer to sit in the wells for about **10 – 15 seconds** before aspiration. Take care not to scratch the surface of the microwells. After the last wash step, empty wells and tap microwell strips on absorbent pad or paper towel to remove excess Wash Buffer. Use the microwell strips immediately after washing. Alternatively microwell strips can be placed upside down on a wet absorbent paper for not longer than 15 minutes. **Do not allow wells to dry.**
- Standard dilution on the microwell plate** (Alternatively the standard dilution can be prepared in tubes – see 9.5.1): Add 100 µl of Sample Diluent in duplicate to all **standard wells**. Pipette 100 µl of undiluted **standard** (concentration = 400 pg/ml) in duplicate into well A1 and A2 (see Table 1). Mix the contents of wells A1 and A2 by repeated aspiration and ejection (concentration of standard 1, S1 = 200 pg/ml), and transfer 100 µl to wells B1 and B2, respectively (see Figure 8). Take care not to scratch the inner surface of the microwells. Continue this procedure 5 times, creating two rows of human LIF standard dilutions ranging from 200.0 to 3.1 pg/ml. Discard 100 µl of the contents from the last microwells (G1, G2) used.

Figure 8



In case of an **external standard dilution** (see 9.5.1), pipette 100 µl of these standard dilutions (S1 - S7) in the standard wells according to Table 1.

Table 1

Table depicting an example of the arrangement of blanks, standards and samples in the microwell strips:

| | 1 | 2 | 3 | 4 |
|----------|--------------------------|--------------------------|----------|----------|
| A | Standard 1 (200.0 pg/ml) | Standard 1 (200.0 pg/ml) | Sample 1 | Sample 1 |
| B | Standard 2 (100.0 pg/ml) | Standard 2 (100.0 pg/ml) | Sample 2 | Sample 2 |
| C | Standard 3 (50.0 pg/ml) | Standard 3 (50.0 pg/ml) | Sample 3 | Sample 3 |
| D | Standard 4 (25.0 pg/ml) | Standard 4 (25.0 pg/ml) | Sample 4 | Sample 4 |
| E | Standard 5 (12.5 pg/ml) | Standard 5 (12.5 pg/ml) | Sample 5 | Sample 5 |
| F | Standard 6 (6.3 pg/ml) | Standard 6 (6.3 pg/ml) | Sample 6 | Sample 6 |
| G | Standard 7 (3.1 pg/ml) | Standard 7 (3.1 pg/ml) | Sample 7 | Sample 7 |
| H | Blank | Blank | Sample 8 | Sample 8 |

- d. Add 100 µl of **Sample Diluent** in duplicate to the **blank wells**.
- e. Add 50 µl of **Sample Diluent** to the **sample wells**.
- f. Add 50 µl of each **sample** in duplicate to the **sample wells**.
- g. Cover with an adhesive film and incubate at room temperature (18 to 25°C) for 2 hours, if available on a microplate shaker set at 100 rpm.
- h. Prepare **Biotin-Conjugate** (see Preparation of Biotin-Conjugate 9.3).
- i. Remove adhesive film and empty wells. **Wash** microwell strips 4 times according to point b. of the test protocol. Proceed immediately to the next step.
- j. Add 100 µl of **Biotin-Conjugate** to all wells.
- k. Cover with an adhesive film and incubate at room temperature (18 to 25°C) for 1 hour, if available on a microplate shaker set at 100 rpm.
- l. Prepare **Streptavidin-HRP** (refer to Preparation of Streptavidin-HRP 9.4).
- m. Remove adhesive film and empty wells. **Wash** microwell strips 4 times according to point b. of the test protocol. Proceed immediately to the next step.
- n. Add 100 µl of diluted **Streptavidin-HRP** to all wells, including the blank wells.
- o. Cover with an adhesive film and incubate at room temperature (18° to 25°C) for 30 minutes, if available on a microplate shaker set at 100 rpm.
- p. Remove adhesive film and empty wells. **Wash** microwell strips 4 times according to point b. of the test protocol. Proceed immediately to the next step.
- q. Pipette 100 µl of **TMB Substrate Solution** to all wells.
- r. Incubate the microwell strips at room temperature (18° to 25°C) for about 10 min. Avoid direct exposure to intense light. **The colour development on the plate should be monitored and the substrate reaction stopped (see next point of this protocol) before positive wells are no longer properly recordable. Determination of the ideal**

time period for colour development has to be done individually for each assay. It is recommended to add the stop solution when the highest standard has developed a dark blue colour. Alternatively the colour development can be monitored by the ELISA reader at 620 nm. The substrate reaction should be stopped as soon as Standard 1 has reached an OD of 0.6 – 0.65.

- s. Stop the enzyme reaction by quickly pipetting 100 µl of **Stop Solution** into each well. It is important that the Stop Solution is spread quickly and uniformly throughout the microwells to completely inactivate the enzyme. Results must be read immediately after the Stop Solution is added or within one hour if the microwell strips are stored at 2 - 8°C in the dark.
- t. Read absorbance of each microwell on a spectro-photometer using 450 nm as the primary wave length (optionally 620 nm as the reference wave length; 610 nm to 650 nm is acceptable). Blank the plate reader according to the manufacturer's instructions by using the blank wells. Determine the absorbance of both the samples and the standards.

Note: In case of incubation without shaking the obtained O.D. values may be lower than indicated below. Nevertheless the results are still valid.

11 CALCULATION OF RESULTS

- Calculate the average absorbance values for each set of duplicate standards and samples. Duplicates should be within 20 per cent of the mean value.
- Create a standard curve by plotting the mean absorbance for each standard concentration on the ordinate against the human LIF concentration on the abscissa. Draw a best fit curve through the points of the graph (a 5-parameter curve fit is recommended).
- To determine the concentration of circulating human LIF for each sample, first find the mean absorbance value on the ordinate and extend a horizontal line to the standard curve. At the point of intersection, extend a vertical line to the abscissa and read the corresponding human LIF concentration.
- **If instructions in this protocol have been followed samples have been diluted 1:2 (50 µl sample + 50 µl Sample Diluent), the concentration read from the standard curve must be multiplied by the dilution factor (x 2).**
- **Calculation of samples with a concentration exceeding standard 1 may result in incorrect human LIF levels. Such samples require further external predilution according to expected human LIF values with Sample Diluent in order to precisely quantitate the actual human LIF level.**
- It is suggested that each testing facility establishes a control sample of known human LIF concentration and runs this additional control with each assay. If the values obtained are not within the expected range of the control, the assay results may be invalid.
- A representative standard curve is shown in Figure 9. This curve cannot be used to derive test results. Each laboratory must prepare a standard curve for each group of microwell strips assayed.

Figure 9
Representative standard curve for human LIF ELISA. Human LIF was diluted in serial 2-fold steps in Sample Diluent. Do not use this standard curve to derive test results. A standard curve must be run for each group of microwell strips assayed.




Table 2

Typical data using the human LIF ELISA

Measuring wavelength: 450 nm

Reference wavelength: 620 nm

| Standard | Human LIF Concentration (pg/ml) | O.D. at 450 nm | Mean O.D. at 450 nm | C.V. (%) |
|----------|---------------------------------|----------------|---------------------|----------|
| 1 | 200.0 | 1.929 | 1.981 | 3.7 |
| | 200.0 | 2.033 | | |
| 2 | 100.0 | 1.127 | 1.125 | 0.3 |
| | 100.0 | 1.122 | | |
| 3 | 50.0 | 0.594 | 0.612 | 4.0 |
| | 50.0 | 0.629 | | |
| 4 | 25.0 | 0.312 | 0.321 | 3.8 |
| | 25.0 | 0.329 | | |
| 5 | 12.5 | 0.190 | 0.184 | 5.0 |
| | 12.5 | 0.177 | | |
| 6 | 6.3 | 0.093 | 0.093 | 0.8 |
| | 6.3 | 0.092 | | |
| 7 | 3.1 | 0.052 | 0.053 | 2.7 |
| | 3.1 | 0.054 | | |
| Blank | 0 | 0.008 | 0.007 | |
| | 0 | 0.006 | | |

The OD values of the standard curve may vary according to the conditions of assay performance (e.g. operator, pipetting technique, washing technique or temperature effects). Furthermore shelf life of the kit may affect enzymatic activity and thus colour intensity. Values measured are still valid.

12 LIMITATIONS

- Since exact conditions may vary from assay to assay, a standard curve must be established for every run.
- Bacterial or fungal contamination of either screen samples or reagents or cross-contamination between reagents may cause erroneous results.
- Disposable pipette tips, flasks or glassware are preferred, reusable glassware must be washed and thoroughly rinsed of all detergents before use.
- Improper or insufficient washing at any stage of the procedure will result in either false positive or false negative results. Empty wells completely before dispensing fresh wash solution, fill with Wash Buffer as indicated for each wash cycle and do not allow wells to sit uncovered or dry for extended periods.

- The use of radioimmunotherapy has significantly increased the number of patients with human anti-mouse IgG antibodies (HAMA). HAMA may interfere with assays utilizing murine monoclonal antibodies leading to both false positive and false negative results. Serum samples containing antibodies to murine immunoglobulins can still be analysed in such assays when murine immunoglobulins (serum, ascitic fluid, or monoclonal antibodies of irrelevant specificity) are added to the sample.

13 PERFORMANCE CHARACTERISTICS

13.1 Sensitivity

The limit of detection of human LIF defined as the analyte concentration resulting in an absorbance significantly higher than that of the dilution medium (mean plus 2 standard deviations) was determined to be 0.7 pg/ml (mean of 6 independent assays).

13.2 Reproducibility

13.2.1 Intra-assay

Reproducibility within the assay was evaluated in 3 independent experiments. Each assay was carried out with 6 replicates of 8 serum samples (spiked or unspiked) containing different concentrations of human LIF. 2 standard curves were run on each plate. Data below show the mean human LIF concentration and the coefficient of variation for each sample (see Table 3). The calculated overall intra-assay coefficient of variation was 5.5%.

Table 3

The mean human LIF concentration and the coefficient of variation for each sample

| Sample | Experiment | Mean Human LIF Concentration (pg/ml) | Coefficient of Variation (%) |
|--------|------------|--------------------------------------|------------------------------|
| 1 | 1 | 245.5 | 5.7 |
| | 2 | 251.2 | 6.9 |
| | 3 | 247.6 | 10.4 |
| 2 | 1 | 201.3 | 0.6 |
| | 2 | 226.9 | 2.1 |
| | 3 | 232.9 | 3.5 |
| 3 | 1 | 164.2 | 4.9 |
| | 2 | 183.9 | 0.8 |
| | 3 | 172.8 | 4.3 |
| 4 | 1 | 87.9 | 7.6 |
| | 2 | 99.9 | 5.5 |
| | 3 | 90.5 | 3.5 |
| 5 | 1 | 72.9 | 6.3 |
| | 2 | 85.0 | 8.9 |
| | 3 | 80.1 | 4.4 |
| 6 | 1 | 50.6 | 5.6 |
| | 2 | 58.9 | 4.6 |
| | 3 | 56.2 | 7.1 |
| 7 | 1 | 31.9 | 5.4 |
| | 2 | 38.9 | 4.2 |
| | 3 | 39.1 | 5.1 |
| 8 | 1 | 24.5 | 7.2 |
| | 2 | 28.3 | 4.5 |
| | 3 | 25.1 | 13.2 |

13.2.2 Inter-assay

Assay to assay reproducibility within one laboratory was evaluated in 3 independent experiments. Each assay was carried out with 6 replicates of 8 serum samples (spiked or unspiked) containing different concentrations of human LIF. 2 standard curves were run on each plate. Data below show the mean human LIF concentration and the coefficient of variation calculated on 18 determinations of each sample (see Table 4). The calculated overall inter-assay coefficient of variation was 7.0%.

Table 4

The mean human LIF concentration and the coefficient of variation of each sample

| Sample | Mean Human LIF Concentration (pg/ml) | Coefficient of Variation (%) |
|--------|--------------------------------------|------------------------------|
| 1 | 248.1 | 1.2 |
| 2 | 222.4 | 6.0 |
| 3 | 173.6 | 5.7 |
| 4 | 92.8 | 6.8 |
| 5 | 79.4 | 7.6 |
| 6 | 55.2 | 7.6 |
| 7 | 36.6 | 11.1 |
| 8 | 26.0 | 7.8 |

13.3 Spikeing Recovery

The spikeing recovery was evaluated by spiking 4 levels of human LIF into pooled normal human serum samples. Recoveries were determined in 3 independent experiments with 8 replicates each. The amount of endogenous human LIF in unspiked serum was subtracted from the spike values. The recovery ranged from 80% to 111% with an overall mean recovery of 90%.

13.4 Dilution Linearity

4 serum samples with different levels of human LIF were analysed at serial 2 fold dilutions with 4 replicates each. The recovery ranged from 98% to 115% with an overall recovery of 109%.

Table 5

| Sample | Dilution | Expected Human LIF Concentration (pg/ml) | Observed Human LIF Concentration (pg/ml) | Recovery of Expected Human LIF Concentration (%) |
|--------|----------|--|--|--|
| 1 | 1:2 | -- | 287.2 | -- |
| | 1:4 | 143.6 | 140.3 | 97.7 |
| | 1:8 | 70.1 | 79.0 | 112.6 |
| | 1:16 | 39.5 | 43.0 | 108.9 |
| 2 | 1:2 | -- | 226.3 | -- |
| | 1:4 | 113.2 | 122.1 | 107.9 |
| | 1:8 | 61.0 | 70.1 | 114.9 |
| | 1:16 | 35.0 | 38.2 | 109.0 |
| 3 | 1:2 | -- | 178.3 | -- |
| | 1:4 | 89.2 | 97.9 | 109.8 |
| | 1:8 | 49.0 | 54.8 | 112.0 |
| | 1:16 | 27.4 | 29.3 | 107.0 |
| 4 | 1:2 | -- | 85.4 | -- |
| | 1:4 | 42.7 | 48.9 | 114.6 |
| | 1:8 | 24.5 | 27.3 | 111.6 |
| | 1:16 | 13.6 | 14.6 | 107.1 |

13.5 Sample Stability

13.5.1 Freeze-Thaw Stability

Aliquots of serum and cell culture supernatant samples (spiked or unspiked) were stored at -20°C and thawed 5 times, and the human LIF levels determined. There was no significant loss of human LIF immunoreactivity detected by freezing and thawing.

13.5.2 Storage Stability

Aliquots of serum and cell culture supernatant samples (spiked or unspiked) were stored at -20°C, 2-8°C, room temperature (RT) and at 37°C, and the human LIF level determined after 24 h. There was no significant loss of human LIF immunoreactivity detected during storage under above conditions.

13.6 Comparison of Serum and Plasma

From 8 individuals, serum as well as EDTA, citrate and heparin plasma obtained at the same time point were evaluated. Human LIF concentrations were not significantly different and therefore all these body fluids are suitable for the assay. It is nevertheless highly recommended to assure the uniformity of blood preparations.

13.7 Specificity

The interference of circulating factors of the immune system was evaluated by spiking these proteins at physiologically relevant concentrations into a human LIF positive serum. There was no crossreactivity detected.

13.8 Expected Values

A panel of 22 serum samples from randomly selected apparently healthy donors (males and females) was tested for human LIF.

There were no detectable human LIF levels found.

Elevated human LIF levels depend on the type of immunological disorder.

14 REFERENCES

- 1) Abe E, Tanaka H, Ishimi Y, Miyaura C, Hayashi T, Nagasawa H, Tomida M, Yamaguchi Y, Hozumi M, Suda T (1986) Differentiating-inducing factor purified from conditioned medium of mitogen-treated spleen cell cultures stimulates bone resorption. *Proc. Natl. Acad. Sci. USA* 83: 5958-5962.
- 2) Alexander HR, Billingsley KG, Block ML, Fraker DL (1994) D-Factor/Leukemia Inhibitory Factor: Evidence for its role as a mediator in acute and chronic inflammatory disease. *Cytokine*, Vol.6, No.6:pp589-596.
- 3) Anegón I, Moreau JF, Godard A, Jacques Y, Peyrat MA, Hallet MM, Wong G, Soullillou JP (1990) Production of HILDA/LIF by activated monocytes. *Cell Immunol.* 130: 50-65.
- 4) Baumann H, Wong GG (1989) Hepatocyte Stimulating Factor III shares structural and functional identity with Leukemia Inhibitory Factor. *J. Immunol.* 143: 1163-1167.
- 5) Dechanet J, Taupin JL, Chomarat P, Rissoan MC, Moreau JF, Banchereau J, Miossec P (1994) Interleukin-4 but not interleukin-10 inhibits the production of leukemia inhibitory factor by rheumatoid synovium and synoviocytes. *Eur. J. Immunol.* 24: 3222-3228.
- 6) Gascan H, Anegón I, Praloran V, Maulet J, Godard A, Soullillou JP, Jacques Y (1990) Constitutive production of human interleukin for DA cells/leukemia inhibitory factor by human tumour cell lines derived from various tissues. *J. Immunol.* 144: 2592-2598.
- 7) Gough NM (1992) Molecular genetics of leukemia inhibitory factor (LIF) and its receptor. *Growth Fact.* 7: 175-179.
- 8) Gough NM, Gearing DP, King JA, Willson TA, Hilton DJ, Nicola NA, Metcalf D (1988) Molecular cloning and expression of the human homologue of the murine gene encoding myeloid leukemia inhibitory factor. *Proc. Natl. Acad. Sci. USA* 85: 2623-2627.
- 9) Ip NY, Nye SH, Boulton TG, Davis S, Taga T, Li Y, Birren SJ, Yasukawa K, Kishimoto T, Anderson DJ, Stahl N, Yancopoulos GD (1992) CNTF and LIF act on neuronal cells via shared signaling pathways that involve the IL-6 signal transducing receptor component gp130. *Cell* 69: 1121-1132.
- 10) Li M, Sendtner M, Smith A (1995) Essential function of LIF receptor in motor neurons. *Nature*, Vol. 378.
- 11) Lorgeot V, Trimoreau F, Gachard N, Praloran V, Denizot Y (1997) Leukemia inhibitory factor concentrations in the bone marrow plasma of healthy subjects and patients with hematologic malignancies. *Eur. Cytokine Netw.*, Vol.8, No. 1: 57-59.
- 12) Metcalf D, Hilton D, Nicola NA (1991) LIF can potentiate murine megakaryocyte production in vitro. *Blood* 77: 2150-2153.
- 13) Moreau JF, Bonneville M, Godard A, Gascan H, Gruart V, Moore MA, Soullillou JP (1987) Characterization of a factor produced by human T cell clones exhibiting eosinophil-activating and burst-promoting activities. *J. Immunol.* 138: 3844-3849.
- 14) Morel D, Taupin JL, Combe C, Potaux L, Gualde N, Moreau JF (1994) One-year enzyme-linked immunosorbent assay follow-up of human interleukin for DA cells/leukemia inhibitory factor in blood and urine of 22 kidney transplant recipients. *Transplantation* Vol.58, No.11: 1190-1195.
- 15) Murphy M. et al. (1991). *Proc. Natl. Acad. Sci USA* 88:3498.

- 16) Paglia D, Oran A, Lu C, Kerbel RS, Sauder DN, McKenzie RC (1995) Expression of leukemia inhibitory factor and interleukin-11 by human melanoma cell lines: LIF, IL-6, and IL-11 are not coregulated. *Journal of Interferon and Cytokine Research* 15: 455-460.
- 17) Reid IR, Lowe C, Cornish J, Skinner SJM, Hilton DJ, Willson TA, Gearing DP, Martin TJ (1990) LIF: a novel bone-active cytokine. *Endocrinology* 126: 1416-1420.
- 18) Rose TM, Bruce AG (1991) Oncostatin M is a member of a cytokine family that includes leukemia-inhibitory factor, granulocyte colony-stimulating factor and interleukin 6. *Proc. Natl. Acad. Sci* 88: 8641-8645.
- 19) Smith AG, Heath JK, Donaldson DD, Wong GG, Moreau JF, Stahl M, Rogers D (1988) Inhibition of pluripotential embryonic stem cells differentiation by purified polypeptides. *Nature* 336: 688-690.
- 20) Taupin JL, Gualde N, Moreau JF (1996) A monoclonal antibody based ELISA for quantitation of human leukemia inhibitory factor. *Cytokine*, Vol.9, No.2: pp112-118.
- 21) Ulich TR, Fann MJ, Patterson PH, Williams JH, Samal B, Del Castillo J, Yin S, Guo K, Remick DG (1994) Intratracheal injection of LPS and cytokines. V. LPS induces expression of LIF and LIF inhibits acute inflammation. *American Physiological Society*.
- 22) Villers D, Dao T, Nguyen JM, Bironneau E, Godard A, Moreau M, De Groote D, Nicolas F, Souillou JP, Anegon I (1995) Increased plasma levels of human interleukin for DA1.a cells/leukemia inhibitory factor in sepsis correlate with shock and poor prognosis. *The Journal of Infectious Diseases* 171: 232-236.
- 23) Waring PM, Romero R, Laham N, Gomez R, Rice GE (1994) Leukemia inhibitory factor: association with intraamniotic infection. *Amm. J. Obstet. Gynecol.* 171 (5): 1335-1341.
- 24) Williams RL, Hilton DJ, Pease S, Willson TA, Stewart CL, Gearing DP, Wagner EF, Metcalf D, Nicola NA, Gough NM (1988) Myeloid leukemia inhibitory factor maintains the developmental potential of embryonic stem cells. *Nature* 336: 684-687.
- 25) Yamamori T. et al. (1989). *Science* 246: 1412.

15 REAGENT PREPARATION SUMMARY

15.1 Wash Buffer (1x)

Add **Wash Buffer Concentrate** 20x (50 ml) to 950 ml distilled water.

| Number of Strips | Wash Buffer Concentrate (ml) | Distilled Water (ml) |
|------------------|------------------------------|----------------------|
| 1 - 6 | 25 | 475 |
| 1 - 12 | 50 | 950 |

15.2 Assay Buffer (1x)

Add **Assay Buffer Concentrate** 20x (5 ml) to 95 ml distilled water.

| Number of Strips | Assay Buffer Concentrate (ml) | Distilled Water (ml) |
|------------------|-------------------------------|----------------------|
| 1 - 6 | 2.5 | 47.5 |
| 1 - 12 | 5.0 | 95.0 |

15.3 Biotin-Conjugate

Make a 1:100 dilution of **Biotin-Conjugate** in Biotin Diluent:

| Number of Strips | Biotin-Conjugate (ml) | Biotin Diluent |
|------------------|-----------------------|----------------|
| 1 - 6 | 0.06 | 5.94 |
| 1 - 12 | 0.12 | 11.88 |

15.4 Streptavidin-HRP

Make a 1:160 dilution of **Streptavidin-HRP** in Assay Buffer (1x):

| Number of Strips | Streptavidin-HRP (ml) | Assay Buffer (1x) (ml) |
|------------------|-----------------------|------------------------|
| 1 - 6 | 0.038 | 5.962 |
| 1 - 12 | 0.075 | 11.925 |

16 TEST PROTOCOL SUMMARY

1. Determine the number of microwell strips required.
2. Wash microwell strips twice with Wash Buffer.
3. Standard dilution on the microwell plate: Add 100 µl Sample Diluent, in duplicate, to all standard wells. Pipette 100 µl prepared standard into the first wells and create standard dilutions by transferring 100 µl from well to well. Discard 100 µl from the last wells. Alternatively external standard dilution in tubes (see 9.5.1): Pipette 100 µl of these standard dilutions in the microwell strips.
4. Add 100 µl Sample Diluent, in duplicate, to the blank wells.
5. Add 50 µl Sample Diluent to sample wells.
6. Add 50 µl sample in duplicate, to designated sample wells.
7. Cover microwell strips and incubate 2 hours at room temperature (18° to 25°C).
8. Prepare Biotin-Conjugate.
9. Empty and wash microwell strips 4 times with Wash Buffer.
10. Add 100 µl Biotin-Conjugate to all wells.
11. Cover microwell strips and incubate 1 hour at room temperature (18° to 25°C).
12. Prepare Streptavidin-HRP.
13. Empty and wash microwell strips 4 times with Wash Buffer.
14. Add 100 µl diluted Streptavidin-HRP to all wells.
15. Cover microwell strips and incubate 30 minutes at room temperature (18° to 25°C).
16. Empty and wash microwell strips 4 times with Wash Buffer.
17. Add 100 µl of TMB Substrate Solution to all wells.
18. Incubate the microwell strips for about 10 minutes at room temperature (18° to 25°C).
19. Add 100 µl Stop Solution to all wells.
20. Blank microwell reader and measure colour intensity at 450 nm.

Note: If instructions in this protocol have been followed samples have been diluted 1:2 (50 µl sample + 50 µl Sample Diluent), the concentration read from the standard curve must be multiplied by the dilution factor (x 2).

NOTES

[REDACTED]



| | | | | |
|---|---|---|---|--|
| HEADQUARTERS: BioVendor Laboratorní medicína, a.s. | CTPark Modrice Evropska 873 | 664 42 Modrice CZECH REPUBLIC | Phone: +420-549-124-185 Fax: +420-549-211-460 | E-mail: info@biovendor.com Web: www.biovendor.com |
| EUROPEAN UNION: BioVendor GmbH | Im Neuenheimer Feld 583 | D-69120 Heidelberg GERMANY | Phone: +49-6221-433-9100 Fax: +49-6221-433-9111 | E-mail: infoEU@biovendor.com |
| USA, CANADA AND MEXICO: BioVendor LLC | 1463 Sand Hill Road Suite 227 | Candler, NC 28715 USA | Phone: +1-828-670-7807 +1-800-404-7807 Fax: +1-828-670-7809 | E-mail: infoUSA@biovendor.com |
| CHINA - Hong Kong Office: BioVendor Laboratories Ltd | Room 4008 Hong Kong Plaza, No.188 | Connaught Road West Hong Kong, CHINA | Phone: +852-2803-0523 Fax: +852-2803-0525 | E-mail: infoHK@biovendor.com |
| CHINA – Mainland Office: BioVendor Laboratories Ltd | Room 2405 YiYa Tower TianYu Garden, No.150 | Lihe Zhong Road Guang Zhou, CHINA | Phone: +86-20-8706-3029 Fax: +86-20-8706-3016 | E-mail: infoCN@biovendor.com |